Cash and equivalents (GAAP) totaled $13.1 million as of Q2 2025. These 10 stocks could mint the next wave of millionaires › Traws Pharma (NASDAQ:TRAW), a clinical-stage biopharmaceutical company ...

GAAP loss per share of ($0.12) in Q2 2025 beat expectations, driven by a sharp drop in research and development costs. No revenue reported, reflecting ongoing clinical-stage operations and focus on ...

The result marks the latest failure for a microbiome therapy in inflammatory bowel disease, which has long been a top target ...

Patient visits are now complete in the final cohort of Phase 1b trial, consisting of Parkinson’s disease patients receiving 300 mg doses of HER-096 or placebo twice weekly over a four-week ...

Q2 2025 Earnings Call Transcript August 13, 2025 PDS Biotechnology Corporation beats earnings expectations. Reported EPS is $ ...

Advancing novel programs for respiratory viruses that pose pandemic threats or risk of serious illness, including SARS CoV2 (ratutrelvir) and influenza (Tivoxavir marboxil, TXM) Prioritization of ratu ...

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing ...

Presented positive results from the phase 3 randomized, placebo-controlled clinical trial of CAN-2409 (aglatimagene ...

Q2 2025 Earnings Call Transcript August 13, 2025 BiomX Inc. beats earnings expectations. Reported EPS is $-0.19, expectations ...

CRISPR Therapeutics advances with promising CTX310 data and key clinical milestones ahead. Click here to read an analysis of ...